Table 1.

Summary results of three NCI-MATCH sub-studies [12–14]

Sub-study	Pts enrolled N	Pts evaluable for response N	PR (%)	SD (%)	PD (%)	PFS6 rate (%)	Pts evaluable for toxicity N	AEs (%)	Grade 3/4 AEs (%)	Comments
Arm W: Pts with FGFR1–3 mutation or translocation receive FGFR Inhibitor AZD4547 [12]	52	41	5	51	44	17	49	80	49	Failed to meet its primary endpoint
Arm Q: Pts with HER2 amplification receive trastuzumab emtansine [13]	N/R	37	8.1	43	N/R	24.8	N/R	N/R	N/R	Failed to meet its primary endpoint
Arm I: Pts with PIK3CA mutation without RAS mutation or PTEN loss receive taselisib [14]	65	N/R	0	N/R	N/R	27	N/R	N/R	N/R	Failed to meet its primary endpoint; Co-occurring mutations were detected in 67% of tumors; 11% of pts. discontinued taselisib because of toxicity

AEs Adverse events, N/R Not reported, OR Objective response, PD Progressive disease, PFS6 Progression-free survival at 6 months of treatment, PR Partial response, Pts Patients, SD Stable disease